Evidence map›Paper›PMID 25416234›Full record

ArticleInternational journal of hematology2015

Aggressive transformation of anaplastic large cell lymphoma with increased number of ALK-translocated chromosomes.

Akihiro Hoshino, Keiko Nomura, Takeru Hamashima, Tomoya Isobe, Masafumi Seki, Mitsuteru Hiwatari, Kenichi Yoshida, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka and 4 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Akihiro HoshinoDepartment of Pediatrics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan, nrb52665@yahoo.co.jp.
Keiko Nomura
Takeru Hamashima
Tomoya Isobe
Masafumi Seki
Mitsuteru Hiwatari
Kenichi Yoshida
Yuichi Shiraishi
Kenichi Chiba
Hiroko Tanaka
Satoru Miyano
Seishi Ogawa
Junko Takita
Hirokazu Kanegane
The University of Tokyo · JPUniversity of Toyama · JPKyoto University · JPTokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pediatric anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) usually has a benign clinical course. A small fraction of patients with ALCL develops an aggressive clinical course; however, its etiology remains unclear. Here we report on an ALK-positive ALCL patient, who had complex translocations with TPM3-ALK revealed by RNA sequencing, with a very aggressive clinical course. On admission, the patient had extraordinarily high white blood cell count with double ALK-translocated chromosomes, and subsequently developed a more aggressive transformation with invasion into multiple organs with triple ALK-translocated chromosomes. The aggressive clinical course may have been related to these additional chromosomal aberrations. Our report provides new insights into the clonal evolution in ALCL and suggests the importance of monitoring examinations including fluorescence in situ hybridization analysis.

Indexed as

Translocation, GeneticAnaplastic Lymphoma KinaseBone MarrowCell Transformation, NeoplasticChild, PreschoolChromosome BreakpointsDisease ProgressionFemaleHumansImmunohistochemistryIn Situ Hybridization, FluorescenceKaryotypeLymphoma, Large-Cell, AnaplasticReceptor Protein-Tyrosine KinasesALK protein, humanAnaplastic Lymphoma KinaseReceptor Protein-Tyrosine Kinases

Identifiers

PMID25416234
OpenAlexW2021543591

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.